You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

 

Online download statistics by month:

Online download statistics by month: May 2022 to July 2025

AbstractFullPdf
May 2022552567179
Jun 2022734763205
Jul 2022549561143
Aug 2022662675154
Sep 202228028250
Oct 202223424161
Nov 202220120344
Dec 202217317441
Jan 202315115152
Feb 202318118450
Mar 202313113260
Apr 2023838543
May 202311411633
Jun 202312212332
Jul 202310210332
Aug 2023989829
Sep 202313013137
Oct 202312312336
Nov 202314214233
Dec 202313813922
Jan 2024707429
Feb 202411311328
Mar 202415715747
Apr 202413213233
May 202411211330
Jun 202415615537
Jul 202413714033
Aug 202412212134
Sep 202413813836
Oct 202417317337
Nov 202417217328
Dec 202416316544
Jan 202517517543
Feb 202518318348
Mar 202515515541
Apr 202514014055
May 202515615682
Jun 202510710738
Jul 2025110
Total746275642059